GM.CD40L, a human bystander cell line created at the Moffitt Cancer Center that expresses both granulocyte-macrophage colony-stimulating factor (GM-CSF) and CD40 ligand (CD40L), has been used to generate an allogeneic tumor cell-based vaccine formulation. The gene discussed is CD40LG; the disease is neoplasm.